Patents by Inventor Hongchang Qu
Hongchang Qu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12115210Abstract: The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and/or chronic weight management, dyslipidemia and/or NASH. The disclosure relates to compounds that agonize the amylin receptor and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity, and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.Type: GrantFiled: March 2, 2022Date of Patent: October 15, 2024Assignee: Eli Lilly and CompanyInventors: Milata Mary Abraham, Daniel Anthony Briere, Lili Guo, Samantha Grace Lyons Keyser, John Lee, Hongchang Qu
-
Publication number: 20240270821Abstract: Polypeptides are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The polypeptides have structural features resulting in activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases and/or conditions such as obesity, chronic weight management, type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, metabolic syndrome, Chronic Kidney Disease (CKD), osteoarthritis (OA), obesity-related sleep apnea (OSA) and polycystic ovary syndrome (PCOS).Type: ApplicationFiled: January 31, 2024Publication date: August 15, 2024Inventors: Milata Mary Abraham, Robert Andrew BROWN, Tamer COSKUN, David Benjamin FLORA, Paul Joseph KLEINDL, Fucheng QU, Hongchang QU, James Lincoln WALLIS
-
Publication number: 20240218031Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.Type: ApplicationFiled: December 20, 2023Publication date: July 4, 2024Inventors: Jorge ALSINA-FERNANDEZ, Andrea Renee GEISER, Lili GUO, Samantha Grace Lyons KEYSER, John LEE, Hongchang QU, William Christopher ROELL
-
Publication number: 20240190936Abstract: Incretin analogs are provided that have activity at each of the GIP. GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus. dyslipidemia. fatty liver disease, metabolic syndrome, non-alcoholic steato-hepatitis and obesity.Type: ApplicationFiled: October 30, 2023Publication date: June 13, 2024Inventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
-
Patent number: 11897926Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.Type: GrantFiled: January 11, 2022Date of Patent: February 13, 2024Assignee: Eli Lilly and CompanyInventors: Jorge Alsina-Fernandez, Andrea Renee Geiser, Lili Guo, Samantha Grace Lyons Keyser, John Lee, Hongchang Qu, William Christopher Roell
-
Patent number: 11834486Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.Type: GrantFiled: December 14, 2018Date of Patent: December 5, 2023Assignee: Eli Lilly and CompanyInventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
-
Publication number: 20230265151Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. These compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). These compounds may be useful in the treatment of obesity.Type: ApplicationFiled: January 21, 2021Publication date: August 24, 2023Inventors: Jorge ALSINA-FERNANDEZ, Robert Andrew BROWN, Robert Chadwick CUMMINS, Mohamed Elsayed Hamed ELSAYED, Andrea Renee GEISER, Xianyin LAI, Hongchang QU, Brian Morgan WATSON
-
Publication number: 20230203121Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.Type: ApplicationFiled: November 21, 2022Publication date: June 29, 2023Inventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
-
Publication number: 20230190945Abstract: The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.Type: ApplicationFiled: October 28, 2022Publication date: June 22, 2023Inventors: Tamer COSKUN, Hongchang QU
-
Publication number: 20230190944Abstract: The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.Type: ApplicationFiled: October 28, 2022Publication date: June 22, 2023Inventors: Tamer COSKUN, Hongchang QU
-
Publication number: 20230102339Abstract: Incretin analogs are provided that have activity at each of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and obesity.Type: ApplicationFiled: December 11, 2020Publication date: March 30, 2023Inventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Tamer Coskun, Hongchang Qu, James Lincoln Wallis
-
Patent number: 11542313Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.Type: GrantFiled: December 14, 2018Date of Patent: January 3, 2023Assignee: Eli Lilly and CompanyInventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
-
Patent number: 11541123Abstract: The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.Type: GrantFiled: December 17, 2021Date of Patent: January 3, 2023Assignee: Eli Lilly and CompanyInventors: Tamer Coskun, Hongchang Qu
-
Publication number: 20220288168Abstract: The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and/or chronic weight management, dyslipidemia and/or NASH. The disclosure relates to compounds that agonize the amylin receptor and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity, and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.Type: ApplicationFiled: March 2, 2022Publication date: September 15, 2022Inventors: Milata Mary ABRAHAM, Daniel Anthony BRIERE, Lili GUO, Samantha Grace Lyons KEYSER, John LEE, Hongchang QU
-
Publication number: 20220193245Abstract: The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.Type: ApplicationFiled: December 17, 2021Publication date: June 23, 2022Inventors: Tamer COSKUN, Hongchang QU
-
Publication number: 20220127315Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.Type: ApplicationFiled: January 11, 2022Publication date: April 28, 2022Inventors: Jorge ALSINA-FERNANDEZ, Andrea Renee GEISER, Lili GUO, Samantha Grace Lyons KEYSER, John LEE, Hongchang QU, William Christopher ROELL
-
Patent number: 11254721Abstract: The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.Type: GrantFiled: July 29, 2020Date of Patent: February 22, 2022Assignee: Eli Lilly and CompanyInventors: Jorge Alsina-Fernandez, Andrea Renee Geiser, Lili Guo, Samantha Grace Lyons Keyser, John Lee, Hongchang Qu, William Christopher Roell
-
Publication number: 20220048967Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.Type: ApplicationFiled: July 2, 2021Publication date: February 17, 2022Inventors: Milata Mary ABRAHAM, Jorge ALSINA-FERNANDEZ, Robert Andrew BROWN, Over CABRERA, Tamer COSKUN, Robert Chadwick CUMMINS, Mohamed ElSayed Hamed ELSAYED, Hongchang QU, James Lincoln WALLIS, Kyle Wynn SLOOP, Francis Stafford WILLARD, Thi Thanh Huyen TRAN, Aktham ABURUB, Phenil Jayantilal PATEL, Amita DATTA-MANNAN, Xianyin LAI
-
Patent number: 11084861Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.Type: GrantFiled: July 22, 2019Date of Patent: August 10, 2021Assignee: Eli Lilly and CompanyInventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Robert Andrew Brown, Over Cabrera, Tamer Coskun, Robert Chadwick Cummins, Mohamed ElSayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Amita Datta-Mannan, Xianyin Lai
-
Publication number: 20210221865Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steato-hepatitis and obesity.Type: ApplicationFiled: December 14, 2018Publication date: July 22, 2021Inventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu